Chen Yangfeng, Xia Han, Zhong Xiaohong
College of Horticulture, Hunan Agricultural University, Changsha, China.
Changsha Central Hospital, Changsha, China.
Front Pharmacol. 2024 Jul 1;15:1389221. doi: 10.3389/fphar.2024.1389221. eCollection 2024.
Pancreatic cancer (PC) is a particularly aggressive malignancy with limited therapeutic options. The search for innovative treatments has focused on traditional Chinese medicine, specifically . This research investigates 's active ingredients, potential targets, and underlying mechanisms in treating PC. High-performance liquid chromatography (HPLC) was used to quantify the active components of and HPLC-Q-TOF-MS was employed for qualitative identification. Potential targets of 's active ingredients were identified using the TCMSP, ETCM, CTD, and Swiss Target Prediction databases. Potential PC-related targets were sourced from DisGeNET, GeneCards, and OMIM databases. A Venn diagram was utilized to identify overlapping PC-related and targets. Core targets and pathways were elucidated through protein-protein interaction (PPI) network analysis, Gene Ontology (GO) assessments, and Reactome pathway enrichment analyses. Molecular docking techniques investigated interactions between active compounds and these targets. The expression and prognostic implications of target genes were evaluated using GEPIA2 and the Human Protein Atlas (HPA) databases. studies assessed the impact of extract (EPE) on Panc-1 cell viability, and Western blot analysis examined the expression levels of key targets. Network pharmacological indicate that econtains active components such as baohuoside I, icariin, hyperoside, and epimedin B, which have potential therapeutic effects against PC. assays confirmed that EPE significantly reduced the viability of Panc-1 cells. Western blot analysis revealed a considerable decrease in the expression of key targets in EPE-treated cells, including AKT1, EGFR, p-EGFR, JUN, BCL2, IL6, and SRC. The R-HSA-1280215: Interleukin-4 and Interleukin-13 signaling pathways involving these genes were identified as potential therapeutic targets. holds promise as a candidate for treating PC. The modulation of interleukin-4 and interleukin-13 signaling pathways could be a pivotal mechanism by which impedes tumor development. Further research is warranted to validate these findings and explore the clinical applicability of in PC treatment.
胰腺癌（PC）是一种侵袭性特别强的恶性肿瘤，治疗选择有限。对创新治疗方法的探索集中在传统中药上，特别是[具体中药名称未给出]。本研究调查了[具体中药名称未给出]治疗PC的活性成分、潜在靶点和潜在机制。采用高效液相色谱（HPLC）对[具体中药名称未给出]的活性成分进行定量，并采用HPLC-Q-TOF-MS进行定性鉴定。利用中药系统药理学数据库（TCMSP）、中药综合数据库（ETCM）、比较毒理基因组学数据库（CTD）和瑞士靶点预测数据库鉴定[具体中药名称未给出]活性成分的潜在靶点。潜在的PC相关靶点来自于疾病基因网络（DisGeNET）、基因卡片（GeneCards）和在线孟德尔人类遗传数据库（OMIM）。利用维恩图确定PC相关靶点与[具体中药名称未给出]靶点的重叠部分。通过蛋白质-蛋白质相互作用（PPI）网络分析、基因本体（GO）评估和Reactome通路富集分析阐明核心靶点和通路。分子对接技术研究活性化合物与这些靶点之间的相互作用。使用GEPIA2和人类蛋白质图谱（HPA）数据库评估靶基因的表达及其预后意义。[具体实验名称未给出]研究评估了[具体中药名称未给出]提取物（EPE）对Panc-1细胞活力的影响，蛋白质印迹分析检测关键靶点的表达水平。网络药理学研究表明，[具体中药名称未给出]含有宝藿苷I、淫羊藿苷、金丝桃苷和朝藿定B等活性成分，对PC具有潜在治疗作用。[具体实验名称未给出]实验证实EPE显著降低了Panc-1细胞的活力。蛋白质印迹分析显示，EPE处理的细胞中关键靶点的表达显著降低，包括AKT1、表皮生长因子受体（EGFR）、磷酸化EGFR（p-EGFR）、原癌基因蛋白（JUN）、B细胞淋巴瘤/白血病-2（BCL2）、白细胞介素-6（IL6）和原癌基因酪氨酸蛋白激酶（SRC）。涉及这些基因的R-HSA-1280215：白细胞介素-4和白细胞介素-13信号通路被确定为潜在治疗靶点。[具体中药名称未给出]有望成为治疗PC的候选药物。调节白细胞介素-4和白细胞介素-13信号通路可能是[具体中药名称未给出]阻碍肿瘤发展的关键机制。有必要进一步研究以验证这些发现，并探索[具体中药名称未给出]在PC治疗中的临床适用性。
